[
  {
    "ts": null,
    "headline": "Gilead snaps up Sprint’s TREX1 immunotherapy programme for $400m",
    "summary": "Gilead’s new immunotherapy asset targets the TREX1 protein, which is a novel target in oncology.",
    "url": "https://finnhub.io/api/news?id=d39b8feaa0bdb300842fd5c794952ccde83816149d750e83573ec18d22b82967",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764093220,
      "headline": "Gilead snaps up Sprint’s TREX1 immunotherapy programme for $400m",
      "id": 137605989,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead’s new immunotherapy asset targets the TREX1 protein, which is a novel target in oncology.",
      "url": "https://finnhub.io/api/news?id=d39b8feaa0bdb300842fd5c794952ccde83816149d750e83573ec18d22b82967"
    }
  },
  {
    "ts": null,
    "headline": "Legend Biotech: Is Carvykti Changing Cancer Treatment Forever?",
    "summary": "Discover why Legend Biotech is rated a 'Strong Buy' as rising Carvykti sales drive growth.",
    "url": "https://finnhub.io/api/news?id=5a5fd84f432763684966abcc7afa84169707557fd4625c77c5b3e5f1fb0f32f8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764081506,
      "headline": "Legend Biotech: Is Carvykti Changing Cancer Treatment Forever?",
      "id": 137606292,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1924268149/image_1924268149.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Discover why Legend Biotech is rated a 'Strong Buy' as rising Carvykti sales drive growth.",
      "url": "https://finnhub.io/api/news?id=5a5fd84f432763684966abcc7afa84169707557fd4625c77c5b3e5f1fb0f32f8"
    }
  },
  {
    "ts": null,
    "headline": "Is Gilead Sciences Stock Outperforming the Dow?",
    "summary": "Gilead Sciences has outperformed the Dow Jones over the past year, and analysts are upbeat about the healthcare stock's prospects.",
    "url": "https://finnhub.io/api/news?id=578488d30ebce0da4115db45a23495497c6ed2478b1c6b03bf9671972dcdaf8c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764076177,
      "headline": "Is Gilead Sciences Stock Outperforming the Dow?",
      "id": 137605990,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences has outperformed the Dow Jones over the past year, and analysts are upbeat about the healthcare stock's prospects.",
      "url": "https://finnhub.io/api/news?id=578488d30ebce0da4115db45a23495497c6ed2478b1c6b03bf9671972dcdaf8c"
    }
  },
  {
    "ts": null,
    "headline": "Tracking Renaissance Technologies (RenTec) 13F Portfolio - Q3 2025 Update",
    "summary": "Explore Renaissance Technologies' Q3 2025 13F portfolio changes. See top stock holdings, key buys & sells, and what it means for your investment strategy.",
    "url": "https://finnhub.io/api/news?id=28e8cae43dd922a8d30bac3d055df24c4cad28fe8f7a944b116293348a263878",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764067254,
      "headline": "Tracking Renaissance Technologies (RenTec) 13F Portfolio - Q3 2025 Update",
      "id": 137604086,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1204194686/image_1204194686.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Explore Renaissance Technologies' Q3 2025 13F portfolio changes. See top stock holdings, key buys & sells, and what it means for your investment strategy.",
      "url": "https://finnhub.io/api/news?id=28e8cae43dd922a8d30bac3d055df24c4cad28fe8f7a944b116293348a263878"
    }
  },
  {
    "ts": null,
    "headline": "Gilead scoops up a preclinical cancer program",
    "summary": "The company, which invested heavily in oncology in recent years, has now put more than $400 million on the table to access a Sprint Bioscience drug targeting “TREX1.”",
    "url": "https://finnhub.io/api/news?id=58ba3b916fdd0c0997266442f698df839317c3f42b59bf0e3a60a887ff5053f1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764065695,
      "headline": "Gilead scoops up a preclinical cancer program",
      "id": 137605991,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The company, which invested heavily in oncology in recent years, has now put more than $400 million on the table to access a Sprint Bioscience drug targeting “TREX1.”",
      "url": "https://finnhub.io/api/news?id=58ba3b916fdd0c0997266442f698df839317c3f42b59bf0e3a60a887ff5053f1"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences: About To Break Out",
    "summary": "Gilead Sciences shows strong growth potential with raised guidance, patent protection, and undervaluation.",
    "url": "https://finnhub.io/api/news?id=9b2831d3012a6b741b97e82b37deb112044c2769fdc8e86e12e6e2d7207d37d6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764051462,
      "headline": "Gilead Sciences: About To Break Out",
      "id": 137602506,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1189813806/image_1189813806.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Gilead Sciences shows strong growth potential with raised guidance, patent protection, and undervaluation.",
      "url": "https://finnhub.io/api/news?id=9b2831d3012a6b741b97e82b37deb112044c2769fdc8e86e12e6e2d7207d37d6"
    }
  }
]